|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:hyaluronidase
gptkb:pertuzumab
gptkb:trastuzumab
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XC63
|
|
gptkbp:brand
|
gptkb:Phesgo
|
|
gptkbp:combines
|
chemotherapy
|
|
gptkbp:contraindication
|
hypersensitivity to active ingredients
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:drugClass
|
monoclonal antibody combination
|
|
gptkbp:form
|
fixed-dose combination
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Phesgo
|
|
gptkbp:indication
|
gptkb:HER2-positive_breast_cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Genentech
|
|
gptkbp:mechanismOfAction
|
HER2 receptor inhibition
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
diarrhea
fatigue
alopecia
peripheral neuropathy
rash
neutropenia
infusion-related reaction
|
|
gptkbp:target
|
gptkb:HER2_protein
|
|
gptkbp:bfsParent
|
gptkb:Roche_Holding_AG
gptkb:F._Hoffmann-La_Roche_AG
gptkb:Hoffmann-La_Roche
|
|
gptkbp:bfsLayer
|
7
|